References
- Barnes P. J. Antiinflammatory actions of corticosteroids: molecular mechanisms. Clin. Sci. 1998; 84: 557–572
- Bazzoni F., Beutler B. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 1996; 334: 1717–1725, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Debets R., Savelkoul H. F.J. Cytokines as cellular communicators. Mediat. Inflamm. 1996; 5: 417–423
- Heufelder A. E., Bahn R. S. Detection and localization of cytokine immunoreactivity in retroocular connective tissue in Graves' ophthalmopathy. Eur. J. Clin. Investig. 1993; 23: 10–17
- Hiromatsu Y., Yang D., Bednarczuk T., Miyake I., Nonaka K., Inoue Y. Cytokine profiles in eye muscle tissue and orbital fat from patients with thyroid associated ophthalmopathy. J. Clin. Endocrinol. Metab. 2000; 85: 1194–1201, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kazim M., Trokel S., Moore S. Treatment of acute Graves' orbitopathy. Ophthalmology 1991; 98: 1443–1448, [PUBMED], [INFOTRIEVE]
- Keil M., Pec M. K., Schenn G., Grunberger T., Kramer G., Fugger R., Steininger R., Muhlbacher F., Balcke P., Stockenhuber F. Value of serum soluble tumour necrosis factor concentrations in the diagnosis and prognosis of renal graft rejection. Nephrol. Dial. Transplant. 1994; 9: 915–919
- Leonardi A., Borghesan F., DePaoli M., Plebani M., Secchi A. G. Procollagens and inflammatory cytokine concentrations in tarsal and limbal vernal keratoconjunctivitis. Exp. Eye Res. 1998; 67: 105–112, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Levine S., Logun C., Chopra D. P., Rhim J. S., Shelhamer J. H. Protein kinase C, Interleukin‐1β, and corticosteroids regulate shedding of the type I, 55 kDa TNF receptor from human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 1996; 14: 254–261, [PUBMED], [INFOTRIEVE], [CSA]
- Liu J., Marino M. W., Wing G., Grail D., Dunn A., Bettadapura J., Slavin A., Old L., Bernard C. C. TNF is a potent anti‐inflammatory cytokine in autoimmune‐mediated demyelinisation. Nat. Med. 1998; 4: 78–83, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mourits M., Koorneef L., Wiersinga W. M., Prummel M. F., Berghout A., Gaag R. D. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br. J. Ophtalmol. 1989; 73: 639–644, [CSA]
- Mysliwiec J., Kretowski A., Topolska J., Siewko K., Jakubczyk D., Szelachowska M., Mikita A., Kinalska I. Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids. Horm. Metab. Res. 2001; 33: 739–743, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Natt N., Bahn R. S. Cytokines in the evolution of Graves' ophthalmopathy. Autoimmunity 1997; 26: 129–133, [PUBMED], [INFOTRIEVE], [CSA]
- Pleyer U., Milani J. K., Ruckert D., Rieck P., Mondino B. J. Determinations of serum tumor necrosis factor alpha in corneal allografts. Ocul. Immunol. Inflamm. 1997; 5: 149–155, [PUBMED], [INFOTRIEVE], [CSA]
- Ramanathan M. A. Physiochemical modelling approach for estimating the stability of soluble receptor‐bound tumor necrosis factor‐alpha. Cytokine 1997; 9: 19–26, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Robak T., Gladalska A., Stepien H. The tumor necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur. Cytokine Netw. 1998; 9: 145–154, [PUBMED], [INFOTRIEVE], [CSA]
- Shimizu T., Tomita Y., Son K., Nishinarita S., Sawada S., Horie T. Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin. Rheumatol. 2000; 19: 352–359, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sytwu H. K., Liblau R. S., McDevitt H. O. The roles of Fas/Apo‐1(CD95) and TNF in antigen‐induced programmed cell death in T cell receptor transgenic mice. Immunity 1996; 5: 17–30, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Valyasevi R. W., Jyonouchi S. C., Dutton C. M., Munsakul N., Bahn R. Effect of tumor necrosis factor‐alpha, interferon‐gamma, and transforming growth factor‐beta on adipogenesis and expression of thyrotropin receptor in human orbital preadipocyte fibroblasts. J. Clin. Endocrinol. Metab. 2001; 86: 903–908, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zhou T., Edwards C. K., Yang P., Wang Z., Bluethmann H., Mountz J. D. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor 1. J. Immunol. 1996; 156: 2661–2665, [PUBMED], [INFOTRIEVE]
- Ziegenhagen M. W., Fitschen J., Martinet N., Schlaak M., Muller‐Quernheim J. Serum level of soluble tumour factor receptor II (75 kDa) indicates inflammatory activity of sarcoidosis. J. Intern. Med. 2000; 248: 33–41, [PUBMED], [INFOTRIEVE], [CROSSREF]